A research team from the Institut de Neurociències of the Universitat Autònoma de Barcelona (INc-UAB) has discovered that the ...

A man whose diseased scalp resembled “an infected sponge of weeping” pus went without proper medical care for more than a year. Another developed tongue cancer after his early symptoms went ignored. A ...

The FDA has granted orphan drug designation (ODD) and RPDD to Arbor Biotechnologies' ABO-101, to treat primary hyperoxaluria ...

Servier Egypt, a leading player in the pharmaceutical industry and part of the global Servier Group, proudly marked its ...

The exploration of natural products and their structural analogues in neuropsychiatry has historically been a fertile area of research, driven by the ...

About Y-mAbs Y-mAbs is a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, radioimmunotherapy and antibody-based therapeutic cancer products. The ...

A small, early trial of a vaccine that mobilizes the immune system to battle advanced kidney cancers appears successf ...

These are known as disease-modifying treatments and have been licensed for private use. Other medications are under review to see if they could be prescribed to people in the very early stages of ...

First-of-its-kind treatment to be approved by FDA in more than a decade, Pradalex is now available to treat swine and bovine respiratory diseases.

Dr. Tycel Phillips discusses the FDA approval of a Calquence combo in MCL, making it the first and only BTK inhibitor ...

The U.S. Food and Drug Administration has approved Journavx (suzetrigine) 50 milligram oral tablets, a first-in-class non-opioid analgesic, to treat moderate to severe acute pain in adults. Journavx ...

Tectonic Therapeutic has done well to advance its Fc-fusion protein candidate TX45 into a phase 2 study targeting patients ...